14-NOV-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL

THERAPEUTIC STUDIES -- ACCRUAL REGISTRATIONS ONLY

COMMITTEE Accrual
Last
12 Months		 Accrual
Last
7 Days		 Yearly
Projection
(7 Days)		 Accrual
Last
30 Days		 Yearly
Projection
(30 Days)		 Accrual
Last
60 Days		 Yearly
Projection
(60 Days)
BREAST 1139 31 1618 104 1266 189 1151
ERLYTX 77 2 104 10 122 15 91
GI 175 9 470 26 317 41 250
GU 417 9 470 53 645 106 645
LEUK 169 1 52 18 219 35 213
LUNG 210 4 209 20 244 33 201
LYMPH 431 8 417 33 402 66 402
MELAN 10 0 0 2 24 3 18
MMYEL 114 3 157 8 97 25 152
MULT 46 1 52 5 61 7 43
OTHER 41 0 0 0 0 2 12
Total 2829 68 3549 279 3397 522 3178

14-NOV-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL

NON-THERAPEUTIC STUDIES -- ACCRUAL REGISTRATIONS ONLY

COMMITTEE Accrual
Last
12 Months		 Accrual
Last
7 Days		 Yearly
Projection
(7 Days)		 Accrual
Last
30 Days		 Yearly
Projection
(30 Days)		 Accrual
Last
60 Days		 Yearly
Projection
(60 Days)
CCD 218 4 209 21 256 40 244
ERLYTX 2 0 0 1 12 1 6
GI 1 0 0 0 0 0 0
GU 6 0 0 1 12 2 12
LEUK 613 13 678 54 657 114 694
LUNG 369 6 313 30 365 72 438
LYMPH 1 0 0 0 0 1 6
OTHER 20 1 52 5 61 5 30
PEOLC 46 0 0 1 12 4 24
PREV 223 4 209 12 146 33 201
SXQOL 654 18 939 65 791 109 664
Total 2153 46 2400 190 2312 381 2319

14-NOV-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL

ACCRUAL REGISTRATIONS ONLY

COMMITTEE Accrual
Last
12 Months		 Accrual
Last
7 Days		 Yearly
Projection
(7 Days)		 Accrual
Last
30 Days		 Yearly
Projection
(30 Days)		 Accrual
Last
60 Days		 Yearly
Projection
(60 Days)
BREAST 1139 31 1618 104 1266 189 1151
CCD 218 4 209 21 256 40 244
ERLYTX 79 2 104 11 134 16 97
GI 176 9 470 26 317 41 250
GU 423 9 470 54 657 108 657
LEUK 782 14 730 72 877 149 907
LUNG 579 10 522 50 609 105 639
LYMPH 432 8 417 33 402 67 408
MELAN 10 0 0 2 24 3 18
MMYEL 114 3 157 8 97 25 152
MULT 46 1 52 5 61 7 43
OTHER 61 1 52 5 61 7 43
PEOLC 46 0 0 1 12 4 24
PREV 223 4 209 12 146 33 201
SXQOL 654 18 939 65 791 109 664
Total 4982 114 5949 469 5710 903 5498

14-NOV-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL

THERAPEUTIC STUDIES - ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

COMMITTEE Accrual
Last
12 Months		 Accrual
Last
7 Days		 Yearly
Projection
(7 Days)		 Accrual
Last
30 Days		 Yearly
Projection
(30 Days)		 Accrual
Last
60 Days		 Yearly
Projection
(60 Days)
BREAST 703 19 991 69 840 123 749
ERLYTX 58 1 52 9 110 14 85
GI 134 3 157 18 219 29 177
GU 308 6 313 40 487 75 457
LEUK 104 0 0 9 110 19 116
LUNG 137 3 157 14 170 22 134
LYMPH 282 6 313 19 231 37 225
MELAN 10 0 0 2 24 3 18
MMYEL 63 1 52 1 12 13 79
MULT 19 0 0 2 24 4 24
OTHER 41 0 0 0 0 2 12
Total 1859 39 2035 183 2227 341 2076

14-NOV-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL

NON-THERAPEUTIC STUDIES - ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

COMMITTEE Accrual
Last
12 Months		 Accrual
Last
7 Days		 Yearly
Projection
(7 Days)		 Accrual
Last
30 Days		 Yearly
Projection
(30 Days)		 Accrual
Last
60 Days		 Yearly
Projection
(60 Days)
CCD 162 4 209 18 219 30 183
ERLYTX 2 0 0 1 12 1 6
GI 1 0 0 0 0 0 0
GU 6 0 0 1 12 2 12
LEUK 248 6 313 24 292 46 280
LUNG 232 6 313 26 317 54 329
LYMPH 1 0 0 0 0 1 6
OTHER 19 0 0 4 49 4 24
PEOLC 39 0 0 1 12 4 24
PREV 223 4 209 12 146 33 201
SXQOL 479 11 574 46 560 79 481
Total 1412 31 1618 133 1619 254 1546

14-NOV-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL

ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

COMMITTEE Accrual
Last
12 Months		 Accrual
Last
7 Days		 Yearly
Projection
(7 Days)		 Accrual
Last
30 Days		 Yearly
Projection
(30 Days)		 Accrual
Last
60 Days		 Yearly
Projection
(60 Days)
BREAST 900 22 1148 89 1084 162 986
CCD 169 4 209 17 207 27 164
ERLYTX 60 1 52 10 122 15 91
GI 146 4 209 17 207 31 189
GU 343 6 313 38 463 75 457
LEUK 355 6 313 33 402 65 396
LUNG 404 10 522 46 560 84 511
LYMPH 283 6 313 19 231 38 231
MELAN 10 0 0 2 24 3 18
MMYEL 63 1 52 1 12 13 79
MULT 38 1 52 1 12 5 30
OTHER 108 0 0 4 49 6 37
PEOLC 44 1 52 5 61 8 49
PREV 223 4 209 12 146 33 201
SXQOL 479 11 574 46 560 79 481
Total 3625 77 4018 340 4140 644 3920

14-NOV-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL

THERAPEUTIC STUDIES COORDINATED BY SWOG

ACCRUAL REGISTRATIONS ONLY

COMMITTEE Accrual
Last
12 Months		 Accrual
Last
7 Days		 Yearly
Projection
(7 Days)		 Accrual
Last
30 Days		 Yearly
Projection
(30 Days)		 Accrual
Last
60 Days		 Yearly
Projection
(60 Days)
BREAST 995 28 1461 92 1120 173 1053
ERLYTX 72 2 104 8 97 13 79
GI 106 8 417 19 231 29 177
GU 307 8 417 41 499 84 511
LEUK 138 1 52 14 170 30 183
LUNG 184 4 209 19 231 30 183
LYMPH 359 6 313 31 377 63 384
MMYEL 101 2 104 7 85 23 140
MULT 46 1 52 5 61 7 43
Total 2308 60 3129 236 2871 452 2753

14-NOV-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL

ACCRUAL REGISTRATIONS ONLY

Inst. Accrual
Last
12 Months		 Accrual
Last
7 Days		 Yearly
Projection
(7 Days)		 Accrual
Last
30 Days		 Yearly
Projection
(30 Days)		 Accrual
Last
60 Days		 Yearly
Projection
(60 Days)
Member 1914 41 2139 188 2289 350 2131
AFFIL 120 3 157 7 85 11 67
CCOP/NCORP 1237 26 1357 121 1473 234 1424
Non-SWOG 1708 41 2139 150 1826 305 1857
Total 4979 111 5792 466 5673 900 5479

14-NOV-2026 6:11

STUDIES CLOSED THIS MONTH

ADMIN STUDYID STNAME REGTYPE Opened? Open Date
LUNG S1900J MET Amplification: Amivantamab Hyaluronidase 1 N 15-OCT-26

14-NOV-2026 6:11

STUDIES WITH 3 OR MORE REGISTRATIONS THIS WEEK

ADMIN STUDYID STNAME REGTYPE Registrations
BREAST S2212 Breast, TNBC, Neoadj Chemo + Pembro 1 22
LEUK MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials 1 13
SXQOL S2205 ICE COMPRESS: Reduction of CIPN from Taxanes 1 11
BREAST S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva 1 11
LUNG LUNGMAP NSCLC, Adv, Master 1 6
SXQOL S2013 I-CHECKIT: ICI toxicity risk prediction study 1 6
BREAST S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva 2 6
GI S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo 1 6
LYMPH S2308 FL, LTB, Mosunetuzumab vs Rituximab 1 5
LUNG LUNGMAP NSCLC, Adv, Master 2 4
PREV NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs 1 4
GU S2419 Renal, adv clear cell, IO +/- Biotx, BIOFRONT 1 4
CCD S2424CD A-PACT vs SOC for GOC communication 1 4
BREAST NRGBR009 Breast, EarlyStg, Adjuvant Chemo 1 3
LUNG S2409 ESCLC, Durvalumab +/- Biomarker Directed Tx 1 3
GU S2427 Blad, MIBC, RT + Pembrolizumab 1 3